Bone marrow transplantation for chronic lymphocytic leukemia

I. W. Flinn, G. Vogelsang

Research output: Contribution to journalReview article

Abstract

The use of bone marrow transplant (BMT) for patients with chronic lymphocytic leukemia (CLL) is a relatively new approach when compared to the use of this therapy for other hematologic malignancies. The long natural history of CLL and significant procedure-related mortality initially deterred the use of BMT for CLL. However, improvement in transplantation procedures and supportive care paved the way for the use of BMT in patients with CLL. There are now multiple reports showing complete remissions with both autologous and allogeneic BMT. The follow-up remains short, therefore, the durability of these remissions remains to be determined. Several innovative approaches to BMT for CLL are now being explored and include non- myeloablative preparative regimens for allogeneic transplants, purging autologous grafts, and induction of graft-versus-leukemia effects. Ultimately, however, long-term disease-free and overall survival will need to be shown before BMT for CLL will gain widespread acceptance.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalSeminars in oncology
Volume25
Issue number1
StatePublished - Mar 10 1998

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Bone marrow transplantation for chronic lymphocytic leukemia'. Together they form a unique fingerprint.

  • Cite this